A new blood test called TriOx has been developed to detect six types of cancer earlier than traditional methods. The test analyzes circulating tumor DNA in blood samples and uses advanced sequencing technology combined with machine learning to identify genetic and epigenetic features. Researchers tested the reliability of TriOx using blood samples from individuals with and without cancer, finding a high sensitivity and specificity rate.
The new test has the potential to improve survival rates by enabling routine blood tests for early detection of cancer. Currently, many cancers are often overlooked until they’ve advanced, making treatment more difficult and less effective. The researchers envision that TriOx could become a simple blood draw method for screening multiple cancers, providing patients and doctors with a faster and more convenient tool to stay ahead of the disease.
The test has been reported in Nature Communications and is now undergoing validation and further testing with more patients and types of cancer. If successful, TriOx may one day be a routine part of cancer screening.
Source: https://www.labroots.com/trending/clinical-and-molecular-dx/28396/blood-test-diagnose-multiple-cancers-stages